Gene expression analyses of immune tumor microenvironment in advanced renal cell carcinoma patients based on response to immunotherapy (Meet-URO 18 I-TME study)
Despite many treatment strategies available for metastatic renal cell carcinoma (mRCC), predictive biomarkers of response to immunotherapy are still needed. In this context, growing efforts have been devoted to translational research, especially focusing on the immune tumor microenvironment (I-TME). The Me...